Database : HANSEN
Search on : RIFABUTINA [Subject descriptor]
References found : 4 [refine]
Displaying: 1 .. 4   in format [Detailed]

page 1 de 1

  1 / 4 HANSEN  
              next record last record
select
to print
Id:13728
Author:DeRossi, Scott S; Hersh, Elliot V
Title:Antibiotics and oral contraceptives ..-
Source:s.l; s.n; 2002. 7 p. ilus, graf.
Abstract:With the exception of rifampin-like drugs, there is a lack of scientific evidence supporting the ability of commonly prescribed antibiotics, including all those routinely employed in outpatient dentistry, to either reduce blood levels and/or the effectiveness of oral contraceptives. To date, all clinical trials studying the effects of concomitant antibiotic therapy (with the exception of rifampin and rifabutin) have failed to demonstrate an interaction. Like all drugs, oral contraceptives are not 100 per cent effective with the failure rate in the typical United States population reported to be as high as 3 per cent. It is thus possible that the case reports of unintended pregnancies during antibiotic therapy may simply represent the normal failure rate of these drugs. Considering that both drug classes are prescribed frequently to women of childbearing potential, one would expect a much higher rate of oral contraceptive failure in this group of patients if a true drug:drug interaction existed. On the other hand, if the interaction does exist but is a relatively rare event, occurring in, say, 1 in 5000 women, clinical studies such as those described in this article would not detect the interaction. The pharmacokinetic studies of simultaneous antibiotic and oral contraceptive ingestion, and the retrospective studies of pregnancy rates among oral contraceptive users exposed to antibiotics, all suffer from one potential common weakness, i.e., their relatively small sample size. Sample sizes in the pharmacokinetic trials ranged from 7 to 24 participants, whereas the largest retrospective study of pregnancy rates still evaluated less than 800 total contraceptive users. Still, the incidence of such a rare interaction would not differ from the accepted normal failure rate of oral contraceptive therapy. The medico-legal ramifications of what looks like at best a rare interaction remains somewhat "murky." On one hand, we have medico-legal experts advising the profession to exercise caution and warn all oral contraceptive users of a potential reduction in efficacy during antibiotic therapy. These opinions are not evidence-based and rely heavily on one or two legal proceedings that cannot even be substantiated. On the other hand, there is one recently published legal proceeding in which the outcome was in favor of the oral surgeon. There is clearly...(AU).
Descriptors:VIES (EPIDEMIOLOGIA)
DISPONIBILIDADE BIOLOGICA
ANTIBIOTICOS/farmacocin
ANTIBIOTICOS/uso terap
ESTUDOS RETROSPECTIVOS
ABSORCAO INTESTINAL/ef drogas
RIFABUTINA/uso terap
RIFAMPINA/uso terap
ANTICONCEPCIONAIS ORAIS/antag
ANTICONCEPCIONAIS ORAIS/farmacocin
ANTICONCEPCIONAIS ORAIS/uso terap
INTERACOES DE MEDICAMENTOS
 ENSAIOS CLINICOS
 JURISPRUDÊNCIA
 TAMANHO DA AMOSTRA
Limits:HUMANO
FEMININO
GRAVIDEZ
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 09018/s


  2 / 4 HANSEN  
              first record previous record next record last record
select
to print
Id:13276
Author:Sanfilippo, A; Della Bruna, C; Marsili, L; Morvillo, E; Pasqualucci, C. R; Schioppacassi, G; Ungheri, D
Title:Biological activity of a new class of rifamycins. Spiro-piperidyl-rifamycins ..-
Source:s.l; s.n; Oct. 1980. 6 p. tab.
Abstract:The biological properties of spiro-piperidyl-rifamycins, a new class of rifamycin antibiotics, are described. In these derivatives the positions 3 and 4 have been incorporated into an imidazolyl ring bearing a spiro-piperidyl group N substituted with linear and branched aliphatic chains. The in vitro antibacterial activity against Staphylococcus aureus and Mycobacterium tuberculosis increases with the number of the carbon atoms in the linera side chain, whereas the inhibitory effect on Escherichia coli is lowered. The antibacterial activity is only marginally affected by branching of the side chain. In vivo (experimental infections of mice) the optimal therapeutic activity against M. tuberculosis is shown by compounds bearing 3 approximately 5 carbon atoms as a linear or branched side chain; in comparison with rifampicin, the potency of these derivatives is 2 approximately 3 times higher. The finding is in a good agreement with the exceptional tissue tropism, which seems to be a favourable property of this group of derivatives.
Descriptors:CINETICA
RIFABUTINA
RIFAMICINAS/metab
RIFAMICINAS/farmacol
DISTRIBUICAO TECIDUAL
INFECCOES BACTERIANAS/quimioter
BACTERIAS/ef drogas
Limits:ANIMAL
FEMININO
CAMUNDONGOS
Electronic Medium:http://www.ilsl.br
Location:BR191.1; 00687/s


  3 / 4 HANSEN  
              first record previous record next record last record
select
to print
Id:11285
Author:Dhople, A. M; Ibanez, M. A
Title:In vivo susceptibility of mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin: anti-leprosy activity of ofloxacin and ansamycins in mice ..-
Source:s.l; s.n; 1994. 3 p. tab.
Descriptors:TATUS
SINERGISMO DE DROGAS

LEPROSTATICOS
HANSENIASE
HANSENIASE
FIGADO
CAMUNDONGOS
CAMUNDONGOS ENDOGAMICOS BALB C
MYCOBACTERIUM LEPRAE
OFLOXACINA
RIFABUTINA
RIFAMPINA
Limits:ANIMAL
Location:BR191.1; 07224/s


  4 / 4 HANSEN  
              first record previous record
select
to print
Id:10148
Author:Dhople, Arvind M; Williams, Sharon L
Title:The activity of rifabutin against Mycobacterium leprae in armadillos ..-
Source:s.l; s.n; 1997. 5 p. tab.
Descriptors:TATUS
MODELOS ANIMAIS DE DOENÇAS
LEPROSTATICOS
LEPROSTATICOS
LEPROSTATICOS
HANSENIASE
HANSENIASE
CAMUNDONGOS
CAMUNDONGOS ENDOGAMICOS BALB C
TESTES DE SENSIBILIDADE MICROBIANA
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
RIFABUTINA
RIFABUTINA
RIFABUTINA
Limits:ANIMAL
Location:BR191.1; 07112/s



page 1 de 1
   


Refine the search
  Database : HANSEN Advanced form   
Search for : Free form   

    Search in field  
1  
2
3
 
           



Search engine: iAH powered by WWWISIS

IAH - © BIREME/PAHO/WHO
Latin American and Caribbean Center on Health Sciences Information